Medifast
Market Cap
US$3.3b
Last Updated
2021/07/31 05:40 UTC
Data Sources
Company Financials +
Executive Summary
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with outstanding track record.
Similar Companies
Share Price & News
How has Medifast's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MED is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MED's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
1.5%
MED
0.5%
US Personal Products
-0.5%
US Market
1 Year Return
70.8%
MED
68.2%
US Personal Products
35.9%
US Market
Return vs Industry: MED exceeded the US Personal Products industry which returned 68.2% over the past year.
Return vs Market: MED exceeded the US Market which returned 35.9% over the past year.
Shareholder returns
| MED | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 0.5% | -0.5% |
| 30 Day | -0.3% | 1.3% | 0.3% |
| 90 Day | 25.7% | 3.2% | 3.1% |
| 1 Year | 75.0%70.8% | 69.6%68.2% | 38.0%35.9% |
| 3 Year | 46.2%33.9% | 94.5%87.2% | 62.9%52.7% |
| 5 Year | 825.1%706.1% | 130.7%112.6% | 121.7%97.3% |
Long-Term Price Volatility Vs. Market
How volatile is Medifast's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
If You Like EPS Growth Then Check Out Medifast (NYSE:MED) Before It's Too Late4 weeks ago | Simply Wall St
Medifast, Inc.'s (NYSE:MED) Stock Is Going Strong: Is the Market Following Fundamentals?1 month ago | Simply Wall St
Medifast (NYSE:MED) Could Be A Buy For Its Upcoming DividendValuation
Is Medifast undervalued compared to its fair value and its price relative to the market?
26.79x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MED ($285.51) is trading above our estimate of fair value ($143)
Significantly Below Fair Value: MED is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MED is poor value based on its PE Ratio (26.8x) compared to the US Personal Products industry average (17.3x).
PE vs Market: MED is poor value based on its PE Ratio (26.8x) compared to the US market (18x).
Price to Earnings Growth Ratio
PEG Ratio: MED is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: MED is overvalued based on its PB Ratio (19.1x) compared to the US Personal Products industry average (3.1x).
Future Growth
How is Medifast forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
19.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MED's forecast earnings growth (19.1% per year) is above the savings rate (2%).
Earnings vs Market: MED's earnings (19.1% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: MED's earnings are forecast to grow, but not significantly.
Revenue vs Market: MED's revenue (19.1% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: MED's revenue (19.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MED's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Medifast performed over the past 5 years?
38.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MED has high quality earnings.
Growing Profit Margin: MED's current net profit margins (11.4%) are higher than last year (10.4%).
Past Earnings Growth Analysis
Earnings Trend: MED's earnings have grown significantly by 38.1% per year over the past 5 years.
Accelerating Growth: MED's earnings growth over the past year (65.8%) exceeds its 5-year average (38.1% per year).
Earnings vs Industry: MED earnings growth over the past year (65.8%) exceeded the Personal Products industry 8.6%.
Return on Equity
High ROE: MED's Return on Equity (71.7%) is considered outstanding.
Financial Health
How is Medifast's financial position?
Financial Position Analysis
Short Term Liabilities: MED's short term assets ($281.9M) exceed its short term liabilities ($144.9M).
Long Term Liabilities: MED's short term assets ($281.9M) exceed its long term liabilities ($6.6M).
Debt to Equity History and Analysis
Debt Level: MED is debt free.
Reducing Debt: MED has not had any debt for past 5 years.
Debt Coverage: MED has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MED has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Medifast current dividend yield, its reliability and sustainability?
1.99%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MED's dividend (1.99%) is higher than the bottom 25% of dividend payers in the US market (1.31%).
High Dividend: MED's dividend (1.99%) is low compared to the top 25% of dividend payers in the US market (3.54%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, MED has been paying a dividend for less than 10 years.
Growing Dividend: MED's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (45.1%), MED's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Dan Chard (56 yo)
4.75yrs
Tenure
US$5,548,874
Compensation
Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December ...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD5.55M) is about average for companies of similar size in the US market ($USD5.31M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: MED's management team is considered experienced (2.3 years average tenure).
Board Members
Experienced Board: MED's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MED insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Medifast, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medifast, Inc.
- Ticker: MED
- Exchange: NYSE
- Founded: 1980
- Industry: Personal Products
- Sector: Household
- Market Cap: US$3.343b
- Shares outstanding: 11.71m
- Website: https://medifastinc.com
Number of Employees
Location
- Medifast, Inc.
- 100 International Drive
- 18th Floor
- Baltimore
- Maryland
- 21202
- United States
Listings
Biography
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/07/31 05:40 |
| End of Day Share Price | 2021/07/30 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.